---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-057153"
form_type: "8-K"
ticker: "BNTC"
cik: "0001808898"
company_name: "Benitec Biopharma Inc."
filed_at: "2025-03-19T23:59:59+00:00"
generated_at: "2026-05-24T12:06:59.625551+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Benitec reports positive Phase 1b/2a BB-301 data; three OPMD subjects show durable swallowing improvements

## Summary
- Subject 1: 41% reduction in total dysphagic symptom burden (SSQ) 12-months post-treatment; VFSS improvements across consistencies.
- Subject 2: 91% reduction in SSQ to 68 units (clinically normal) at 12 months; pathologic sequential swallows dropped from 80% to 17%.
- Subject 3: 68% reduction in SSQ to 70 units (clinically normal) at 3 months; zero pathologic sequential swallows observed.
- No severe adverse events reported; sixth and final Cohort 1 subject expected to receive low-dose BB-301 in Q2 2025.

## SEC filing metadata
- accession: 0001193125-25-057153
- form_type: 8-K
- ticker: BNTC
- cik: 0001808898
- company_name: Benitec Biopharma Inc.
- filed_at: 2025-03-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808898/000119312525057153/0001193125-25-057153-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808898/000119312525057153/d820411d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-057153
- JSON: https://secwatch.observer/filing/0001193125-25-057153.json
- Plain text: https://secwatch.observer/filing/0001193125-25-057153.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.